文献速递淋巴瘤

原发中枢神经系统淋巴瘤患者来源类器官的建立与分子表征

Establishment and molecular characterisation of patient-derived organoids for primary central nervous system lymphoma.
PubMed 文献 · Leukemia · 2025-03-18

研究建立了原发中枢神经系统淋巴瘤(PCNSL)患者来源类器官(CLO)的培养方法,并通过组织病理学、单核RNA测序、批量RNA测序和全外显子测序进行分子表征。CLO在2周内生成,能准确模拟原发肿瘤的组织学特征、基因表达谱和突变谱。对3例CLO进行4种标准药物敏感性检测,显示对甲氨蝶呤敏感,对地塞米松、依鲁替尼和利妥昔单抗耐药。

要点

  • 原发中枢神经系统淋巴瘤患者来源类器官(CLO)可在2周内快速建立。
  • CLO能准确模拟原发肿瘤的组织学、基因表达和突变特征。
  • 3例CLO对甲氨蝶呤敏感,对地塞米松、依鲁替尼和利妥昔单抗耐药。

核心结论

  • CLO能有效模拟PCNSL的关键特征,为探索个体化治疗策略提供快速可靠平台,可能加速研究成果向临床实践转化。

研究设计与样本

  • 研究建立了PCNSL患者来源类器官(CLO)的培养方法,并通过组织病理学分析、单核RNA测序、批量RNA测序和全外显子测序进行广泛分子表征。

主要发现

  • CLO在2周内生成,准确模拟了原发肿瘤的组织学属性、基因表达景观和突变谱。
  • 单核RNA测序显示CLO保持了原发肿瘤的细胞类型异质性和分子特征。
  • 对3例选定CLO进行4种标准药物敏感性检测,CLO对甲氨蝶呤表现出特异性敏感,对地塞米松、依鲁替尼和利妥昔单抗耐药。

临床怎么用

  • 作者认为CLO可能成为反映药物敏感性的有价值工具,为探索个体化治疗策略提供快速可靠平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary central nervous system lymphoma (PCNSL) exhibits substantial intratumoural and intertumoural heterogeneity, complicating the development of effective treatment methods. Existing in vitro models fail to simulate the cellular and mutational diversity of native tumours and require prolonged generation times. Therefore, we developed a culture method for patient-derived PCNSL organoids (CLOs) and evaluated the organoids through extensive molecular characterisation, histopathological analysis, single-nucleus RNA sequencing, bulk RNA sequencing and whole-exome sequencing. These CLOs accurately mimicked the histological attributes, gene expression landscapes and mutational profiles of their original tumours. Single-nucleus RNA sequencing also revealed that CLOs maintained cell-type heterogeneity and the molecular signatures of their original tumours. CLOs were generated within 2 weeks, demonstrating rapid development and reliability. Therapeutic profiling was performed on three selected CLOs treated with four standard drugs. The CLOs exhibited specific sensitivity to methotrexate, and resistance to dexamethasone, ibrutinib and rituximab, suggesting that CLOs may be valuable tools for reflecting drug sensitivities. Taken together, these results emphasise that CLOs effectively emulate the key characteristics of PCNSL, increasing the understanding of the genetic landscape of this complex disease. CLOs provide a rapid and reliable platform for exploring individualised treatment strategies, potentially accelerating the transition of research findings to clinical practice.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li S, Ren J, Wu J, et al. Establishment and molecular characterisation of patient-derived organoids for primary central nervous system lymphoma. Leukemia. 2025. PMID: 40102628. doi:10.1038/s41375-025-02562-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。